转移性去势抵抗性前列腺癌接受225Ac-PSMA-617放射配体治疗的总体生存与无病生存预测因素
本研究纳入73例转移性去势抵抗性前列腺癌患者,接受225Ac-PSMA-617放射配体治疗,共210个周期。70%患者PSA下降≥50%,82%患者任何PSA下降;估计中位无进展生存期(PFS)为15.2个月(95%CI 13.1-17.4),中位总生存期(OS)为18个月(95%CI 16.2-19.9)。多因素分析显示PSA下降≥50%与OS和PFS显著相关,既往177Lu-PSMA治疗与PFS负相关。
要点
- 225Ac-PSMA-617治疗后PSA下降≥50%是多因素分析中与OS和PFS显著相关的因素。
- 既往177Lu-PSMA治疗在单因素和多因素分析中均与PFS负相关。
- 常见不良反应为口干(85%),3/4级肾功能衰竭见于5例基线肾功能损害患者。
核心结论
- 225Ac-PSMA-617治疗后PSA下降≥50%经多因素分析证实与OS和PFS显著相关。
- 既往177Lu-PSMA治疗在单因素和多因素分析中均与PFS负相关。
研究设计与样本
- 本研究为单中心经验报告,纳入73例转移性去势抵抗性前列腺癌患者,这些患者已耗尽可用治疗选项。
- 患者接受225Ac-PSMA-617治疗,共210个周期;基线及随访时进行全血细胞计数、肾小球滤过率和肝功能检查以评估毒性。
- 基线、每周期治疗前及随访时进行68Ga-PSMA PET/CT用于患者选择、确定治疗药物活度和疗效评估;系列PSA用于PSA反应评估。
主要发现
- 73例男性患者(平均年龄69岁,范围45-85岁)接受225Ac-PSMA-617治疗,共210个周期。
- 70%患者获得PSA下降≥50%,82%患者出现任何PSA下降;29%患者68Ga-PSMA PET上所有病灶消退。
- 随访期间23例患者出现疾病进展,13例患者死于疾病。
- 估计中位PFS为15.2个月(95%CI 13.1-17.4),中位OS为18个月(95%CI 16.2-19.9)。
- 单因素分析中,基线PSA、任何PSA下降、PSA下降≥50%、既往化疗、既往放疗和基线血红蛋白水平与更长的PFS和OS相关(所有P<0.05)。
关键数值与推荐
- 多因素分析中,既往177Lu-PSMA治疗与PFS呈负相关,PSA下降≥50%与PFS呈正相关。
- 多因素分析中,仅PSA下降≥50%与OS保持显著相关。
- 口干见于85%患者,但严重程度未至需要终止治疗;贫血见于27例患者;无患者出现IV级骨髓毒性;3级或4级肾功能衰竭见于5例基线肾功能损害患者。
临床怎么用
- 对于转移性去势抵抗性前列腺癌患者,225Ac-PSMA-617治疗后可依据PSA下降≥50%评估生存获益。
- 既往接受过177Lu-PSMA治疗的患者,接受225Ac-PSMA-617治疗时PFS可能较短,需予以关注。
- 治疗期间需监测口干、贫血和肾功能,尤其基线肾功能损害患者应警惕3/4级肾功能衰竭。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metastatic prostate carcinoma overexpresses prostate-specific membrane antigen (PSMA), making this antigen a suitable target for radioligand therapy of the disease. Here we report on our experience with a series of 73 castration-resistant prostate carcinoma patients treated with 225Ac-PSMA-617, identifying variables predictive for overall survival (OS) and progression-free survival (PFS) after 225Ac-PSMA-617 treatment. Methods:225Ac-PSMA-617 was administered to patients who had metastatic castration-resistant prostate carcinoma and who had exhausted available therapy options for their disease. Full blood count, glomerular filtration rate, and liver function test were obtained at baseline and on follow-up for evaluation of toxicity. 68Ga-PSMA PET/CT was obtained at baseline, before every treatment cycle, and on follow-up for selection of patients for treatment, to determine the activity of the treatment agent to be administered, and for response assessment. Serial prostate-specific antigen (PSA) was obtained for PSA response assessment. Results: Seventy-three men (mean age, 69 y; range, 45-85 y) with metastatic castration-resistant prostate carcinoma were treated with 210 cycles of 225Ac-PSMA-617. In 70% of patients, a PSA decline of greater than or equal to 50% was obtained; 82% of patients had any PSA decline. In 29% of patients, all lesions on 68Ga-PSMA PET resolved in response to treatment. During follow-up, 23 patients experienced disease progression, whereas 13 patients died from their disease. The estimated median PFS and OS were 15.2 mo (95% CI, 13.1-17.4) and 18 mo (95% CI, 16.2-19.9), respectively. In univariate analyses, factors such as baseline PSA, any PSA decline, PSA decline of greater than or equal to 50%, prior chemotherapy, prior radiation therapy, and baseline hemoglobin level were associated with longer PFS and OS (all Ps < 0.05). In multivariate analyses, there was a negative association between prior 177Lu-PSMA therapy and PFS, and a positive association between PSA decline of greater or equal to 50% and PFS. Only a PSA decline of greater than or equal to 50% remained significantly associated with OS on multivariate analyses. Xerostomia was seen in 85% of patients but was not severe enough to warrant discontinuing treatment. Anemia was seen in 27 patients; no patients had grade IV bone marrow toxicity. Renal failure of grade III or IV was seen in 5 patients with baseline renal impairment. Conclusion: In this study, a PSA decline of greater than or equal to 50% after treatment with 225Ac-PSMA-617 was proven by multivariate analyses to be significantly associated with OS and PFS. Furthermore, previous 177Lu-PSMA treatment was negatively associated with PFS in both univariate and multivariate analyses.
引用
- Sathekge M, Bruchertseifer F, Vorster M, et al. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy. J Nucl Med. 2019. PMID: 31101746. doi:10.2967/jnumed.119.229229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。